COVID-19 from a cardiovascular perspective
Currently, myocardial injury has been reported in patients hospitalized with coronavirus disease 2019 (COVID-19). The studies also show a correlation between cardiac events and severe forms of the disease. COVID-19 begins with an early infection phase in which the virus infiltrates the lung parenchyma and proliferates. It then progresses to the pulmonary phase, where the initial inflammatory process, characterized by vasodilation, vascular permeability, and leukocyte recruitment, leads to lung damage, hypoxemia, and cardiovascular stress. The renin angiotensin aldosterone system is important in the pathophysiology of severe acute respiratory syndrome coronavirus 2 infection and in the propagation of systemic inflammation. Within this system, the pathway mediated by angiotensin-converting enzyme 2 (ACE2) produces vasodilation, cardioprotection, anti-oxidation, and anti-inflammation. Furthermore, the free form of ECA2 prevents binding of the virus to host cells and reduces its damage to the lung.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:91 |
|---|---|
| Enthalten in: |
Archivos de cardiologia de Mexico - 91(2021), Suplemento COVID vom: 20. Dez., Seite 086-094 |
| Sprache: |
Spanisch |
|---|
| Weiterer Titel: |
COVID-19 desde una perspectiva cardiovascular |
|---|
| Beteiligte Personen: |
Bryce-Moncloa, Alfonso [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ACE2 protein, human |
|---|
| Anmerkungen: |
Date Completed 02.02.2022 Date Revised 08.05.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.24875/ACM.20000304 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM324261012 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM324261012 | ||
| 003 | DE-627 | ||
| 005 | 20231225185933.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||spa c | ||
| 024 | 7 | |a 10.24875/ACM.20000304 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1080.xml |
| 035 | |a (DE-627)NLM324261012 | ||
| 035 | |a (NLM)33871468 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a spa | ||
| 100 | 1 | |a Bryce-Moncloa, Alfonso |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 from a cardiovascular perspective |
| 246 | 3 | 3 | |a COVID-19 desde una perspectiva cardiovascular |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.02.2022 | ||
| 500 | |a Date Revised 08.05.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Currently, myocardial injury has been reported in patients hospitalized with coronavirus disease 2019 (COVID-19). The studies also show a correlation between cardiac events and severe forms of the disease. COVID-19 begins with an early infection phase in which the virus infiltrates the lung parenchyma and proliferates. It then progresses to the pulmonary phase, where the initial inflammatory process, characterized by vasodilation, vascular permeability, and leukocyte recruitment, leads to lung damage, hypoxemia, and cardiovascular stress. The renin angiotensin aldosterone system is important in the pathophysiology of severe acute respiratory syndrome coronavirus 2 infection and in the propagation of systemic inflammation. Within this system, the pathway mediated by angiotensin-converting enzyme 2 (ACE2) produces vasodilation, cardioprotection, anti-oxidation, and anti-inflammation. Furthermore, the free form of ECA2 prevents binding of the virus to host cells and reduces its damage to the lung | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Pandemia | |
| 650 | 4 | |a Cardiovascular | |
| 650 | 4 | |a ECA2 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 7 | |a ACE2 protein, human |2 NLM | |
| 650 | 7 | |a EC 3.4.17.23 |2 NLM | |
| 650 | 7 | |a Angiotensin-Converting Enzyme 2 |2 NLM | |
| 650 | 7 | |a EC 3.4.17.23 |2 NLM | |
| 700 | 1 | |a Bryce-Alberti, Mayte |e verfasserin |4 aut | |
| 700 | 1 | |a Portmann-Baracco, Arianna |e verfasserin |4 aut | |
| 700 | 1 | |a Urquiaga-Calderón, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Larrauri-Vigna, César |e verfasserin |4 aut | |
| 700 | 1 | |a Alegría-Valdivia, Edmundo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Archivos de cardiologia de Mexico |d 2001 |g 91(2021), Suplemento COVID vom: 20. Dez., Seite 086-094 |w (DE-627)NLM114616272 |x 1665-1731 |7 nnns |
| 773 | 1 | 8 | |g volume:91 |g year:2021 |g number:Suplemento COVID |g day:20 |g month:12 |g pages:086-094 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.24875/ACM.20000304 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 91 |j 2021 |e Suplemento COVID |b 20 |c 12 |h 086-094 | ||